-- Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $58.9M, vs. Street Est of $54.1M
4:34PM ET 5/03/2022 MT Newswires...
Quotes Snapshot > MDXG
MiMedx Group Inc MDXG:NASDAQ
Last Price$3.60NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$3.60 (15)
Ask (Size)$3.61 (147)
Day Low / HighN/A - N/A
Volume341.2 K
Read more news Recent News
MiMedx Group to Launch Exclusive Version of WoundGenex's Premier Graft Program in US; Shares Gain
10:30AM ET 3/16/2022 MT NewswiresMiMedx Group (MDXG) has entered a partnership to launch an exclusive version of wound care management firm WoundGenex's Premier Graft Program for its...
MiMedx Group Swings to Q4 Income, Revenue Declines
5:09PM ET 2/28/2022 MT NewswiresMiMedx Group (MDXG) on Monday reported Q4 earnings of $0.01 per diluted share, compared with a loss of $0.17 a year ago. Analysts polled by Capital IQ also...
-- Earnings Flash (MDXG) MIMEDX GROUP Posts Q4 Revenue $67.4M, vs. Street Est of $63.7M
4:07PM ET 2/28/2022 MT Newswires...
View all Commentary and Analysis
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q1 2022 Results - Earnings Call Transcript
2:39PM ET 5/04/2022 Seeking AlphaMiMedx Group (MDXG) Presents at the Canaccord Genuity Musculoskeletal Conference - Slideshow
7:01AM ET 3/27/2022 Seeking AlphaMiMedx Group, Inc. (MDXG) CEO Tim Wright on Q4 2021 Results - Earnings Call Transcript
9:30PM ET 2/28/2022 Seeking AlphaMiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2021 Results - Earnings Call Transcript
3:45PM ET 11/03/2021 Seeking AlphaCompany Profile
Business DescriptionMiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA. View company web site for more details
| Address | 1775 West Oak Commons Court NE Marietta, Georgia 30062 |
| Phone | +1.770.651.9100 |
| Number of Employees | 690 |
| Recent SEC Filing | 05/20/2022 DEFA14A |
| Chief Executive Officer & Director | Timothy R. Wright |
| Senior Vice President-Operations & Procurement | Scott M. Turner |
| Chief Financial Officer | Peter M. Carlson |
| Chief Medical Officer | David H. Mason |
Company Highlights
| Price Open | $3.68 |
| Previous Close | $3.61 |
| 52 Week Range | $3.27 - 15.99 |
| Market Capitalization | $408.1 M |
| Shares Outstanding | 113.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.17 |
| Beta vs. S&P 500 | N/A |
| Revenue | $245.0 M |
| Net Profit Margin | -4.81% |
| Return on Equity | -14.18% |
Analyst Ratings as of 07/23/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |